Sangamo Therapeutics
SGMOQ · OTC · United States
Share price · SGMOQ
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when SGMOQ's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 3 Aug 2026+28.6%
Nothing announced by SGMOQ that day or the session before.
- 24 Jun 2026-28.6%
- 23 Jun 2026-58.8%
- 5 May 2026-38.9%
Nothing announced by SGMOQ that day or the session before.
- 4 May 2026+28.6%
Nothing announced by SGMOQ that day or the session before.
- 1 May 2026+16.7%
Nothing announced by SGMOQ that day or the session before.
- 29 Apr 2026-35.0%
- 24 Apr 2026-26.9%
Nothing announced by SGMOQ that day or the session before.
- 31 Mar 2026-19.4%
- 24 Feb 2026+20.5%
Nothing announced by SGMOQ that day or the session before.
Share of unusual movement by asset
For each asset, the share of SGMOQ's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
| Asset | Event days | Share of unusual movement |
|---|---|---|
| Other company news (earnings, financing, releases naming no asset) | — | 36% |
| Sessions with no dated event | — | 64% |
No dated announcements about its assets since 2 Jul 2024.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1/2 | HLA-A*02 (CAR-Treg)Cell therapy | Organ Transplant Rejection Kidney Transplant Rejection Prophylaxis |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Financial reports
Quarterly & interim (14)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $1.4M | $27M | $28M | $31M-$19M operating cash flow | report ↗ |
View 13 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-Q3 | $0.6M | $28M | $31M+ $0 short-term inv. | $35M-$29M operating cash flow | report ↗ |
| 2025-Q2 | $18M | $27M | $40M+ $0 short-term inv. | $20M-$18M operating cash flow | report ↗ |
| 2025-Q1 | $6.4M | $26M | $27M+ $0 short-term inv. | $31M-$26M operating cash flow | report ↗ |
| 2024-Q3 | $49M | $28M | $41M+ $0 short-term inv. | —$12M operating cash flow | report ↗ |
| 2024-Q2 | $0.4M | $24M | $28M+ $0 short-term inv. | $36M-$27M operating cash flow | report ↗ |
| 2024-Q1 | $0.5M | $36M | $55M+ $0 short-term inv. | $49M-$49M operating cash flow | report ↗ |
| 2023-Q3 | $9.4M | $57M | $58M+ $76M short-term inv. | $104M-$47M operating cash flow | report ↗ |
| 2023-Q2 | $6.8M | $63M | $68M+ $76M short-term inv. | $115M-$61M operating cash flow | report ↗ |
| 2023-Q1 | $158M | $63M | $80M+ $127M short-term inv. | —-$66M operating cash flow | report ↗ |
| 2022-Q3 | $26M | $65M | $96M+ $219M short-term inv. | $53M-$54M operating cash flow | report ↗ |
| 2022-Q2 | $29M | $60M | $119M+ $198M short-term inv. | $43M-$54M operating cash flow | report ↗ |
| 2022-Q1 | $28M | $59M | $122M+ $198M short-term inv. | $44M-$59M operating cash flow | report ↗ |
| 2021-Q3 | $29M | $63M | $178M+ $246M short-term inv. | $48M-$59M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | $40M | $113M | $21M+ $0 short-term inv. | $31M-$97M operating cash flow | report ↗ |
Sangamo Therapeutics reported full-year 2025 revenue of $39.55M, down 31.6% YoY, with R&D spend of $112.67M, up 1.0% YoY. The company held cash and equivalents of $20.95M, reported a net loss of $122.93M, and a quarterly net burn of $122.93M.
During the year, Sangamo initiated a rolling BLA submission for isaralgagene civaparvovec in Fabry disease, received FDA Fast Track designation for ST-503 in small fiber neuropathy, advanced CTA-enabling activities for ST-506 in prion disease, and regained development and commercialization rights to the hemophilia A candidate giroctocogene fitelparvovec from Pfizer. The company is pursuing collaboration agreements to fund operations and disclosed substantial doubt about its ability to continue as a going concern.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | $58M | $112M | $43M+ $0 short-term inv. | $24M-$67M operating cash flow | report ↗ |
| 2023-FY | $176M | $234M | $47M+ $36M short-term inv. | $64M-$225M operating cash flow | report ↗ |
| 2022-FY | $111M | $250M | $102M+ $177M short-term inv. | $48M-$224M operating cash flow | report ↗ |
| 2021-FY | $111M | $231M | $180M+ $198M short-term inv. | $45M-$233M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 2 sales ($107K). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-05-25 | Macrae Sandy · director, PRESIDENT, CEO AND DIRECTOR | Tax withholding | 12,613 | $0.17 | $2K | Form 4 |
| 2026-05-25 | Willoughby Scott B. · SVP, CHIEF LEGAL OFFICER, SECY | Tax withholding | 4,036 | $0.17 | $703 | Form 4 |
| 2026-05-25 | Dubois-Stringfellow Nathalie · SVP-CHIEF DEVELOPMENT OFFICER | Tax withholding | 4,036 | $0.17 | $703 | Form 4 |
| 2026-05-25 | Jain Nikunj · Principal Accounting Officer | Tax withholding | 1,919 | $0.17 | $334 | Form 4 |
| 2026-05-25 | Davis Gregory D · Head of Research & Technology | Tax withholding | 1,630 | $0.17 | $284 | Form 4 |
| 2026-04-22 | Davis Gregory D · Head of Research & Technology | Open-market sale | 69,827 | $0.25 | $18K | Form 4 |
| 2026-04-21 | Dubois-Stringfellow Nathalie · SVP-CHIEF DEVELOPMENT OFFICER | Open-market sale | 345,942 | $0.26 | $89K | Form 4 |
| 2026-04-01 | Willoughby Scott B. · SVP, CHIEF LEGAL OFFICER, SECY | Award / grant (derivative) | 800,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 112 reporting institutions held 105.4M shares ($26.0M, 25.4% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | ARMISTICE CAPITAL, LLC | 40,400,067 | $10.0M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 12,704,408 | $3.1M |
| 3 | TWO SIGMA INVESTMENTS, LP | 6,270,441 | $1.5M |
| 4 | Balyasny Asset Management L.P. | 5,288,097 | $1.3M |
| 5 | GEODE CAPITAL MANAGEMENT, LLC | 4,570,862 | $1.1M |
| 6 | BlackRock, Inc. | 4,547,848 | $1.1M |
| 7 | RENAISSANCE TECHNOLOGIES LLC | 3,836,665 | $947K |
| 8 | UBS Group AG | 2,570,992 | $635K |
| 9 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 2,352,360 | $581K |
| 10 | VANGUARD FIDUCIARY TRUST CO | 2,310,297 | $571K |
| 11 | JACOBS LEVY EQUITY MANAGEMENT, INC | 2,050,384 | $506K |
| 12 | BANK OF AMERICA CORP /DE/ | 1,838,390 | $452K |
| 13 | STATE STREET CORP | 1,694,783 | $418K |
| 14 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 1,687,463 | $417K |
| 15 | LUMINUS MANAGEMENT LLC | 1,681,089 | $415K |